Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients

Neuropsychopharmacology

Volumn 36, Issue 6, 2011, Pages 1219-1226

  Bergamaschi, Mateus M ^a,b   Queiroz, Regina Helena Costa ^a,b   Chagas, Marcos Hortes Nisihara ^a,b   De Oliveira, Danielle Chaves Gomes ^a,b   De Martinis, Bruno Spinosa ^a,b   Kapczinski, Flávio ^b,c   Quevedo, Joo ^b,d   Roesler, Rafael ^b,e   Schröder, Nadja ^b,f   Nardi, Antonio E ^b,g   Martín Santos, Rocio ^b,h   Hallak, Jaime Eduardo Cecílio ^a,b   Zuardi, Antonio Waldo ^a,b   Crippa, José Alexandre S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

anxiety; cannabidiol; CBD; simulation of public speaking test; social anxiety disorder; SPST

Indexed keywords

CANNABIDIOL; PLACEBO;

ADULT; ANXIETY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART RATE; HUMAN; MALE; NEGATIVE SELF STATEMENT SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PUBLIC SPEAKING; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN CONDUCTANCE; SOCIAL PHOBIA; SPEECH ANALYSIS; SPEECH DISORDER; VISUAL ANALOG SCALE;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CANNABIDIOL; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PHOBIC DISORDERS; PHYSICAL EXAMINATION; PLACEBOS; SPEECH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954608618     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2011.6     Document Type: Article

References (45)

1. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L (1981). Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37: 1090-1092. (Pubitemid 12179489)
2. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H et al (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21-43. (Pubitemid 16077324)
3. Blanco C, Antia SX, Liebowitz MR (2002). Pharmacotherapy of social anxiety disorder. Biol Psychiatry 51: 109-120. (Pubitemid 34093799)
4. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML et al (2008). Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966-973.
5. Brunello N, den Boer JA, Judd LL, Kasper S, Kelsey JE, Lader M et al (2000). Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord 60: 61-74. (Pubitemid 30625246)
6. Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM (2008). Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 42: 230-239. (Pubitemid 350266725)
7. Campos AC, Guimaraes FS (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199: 223-230.
8. Canadian Psychiatric Association (2006). Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatryi 51(Suppl 2): 9-91.
9. Chagas MH, Nardi AE, Manfro GG, Hetem LA, Andrada NC, Levitan MN et al (2010). Guidelines of the Brazilian medical Association for the diagnosis and differential diagnosis of social anxiety disorder. Rev Bras Psiquiatr 32: 444-452.
10. Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH (2000). Psychometric properties of Social Phobia Inventory (SPIN). Br J Psychiatry 176: 379-386.
11. Connor KM, Kobak KA, Churchill LE, Katzelnick D, Davidson JR (2001). Mini-Spin: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety 14: 137-140. (Pubitemid 32937487)
12. Crippa JA, de Lima Osrio F, Del-Ben CM, Filho AS, da Silva Freitas MC, Loureiro SR (2008a). Comparability between telephone and face-to-face structured clinical interview for DSM-IV in assessing social anxiety disorder. Perspect Psychiatr Care 44: 241-247.
13. Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran F, Marti N-Santos RO et al (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorderFa preliminary report. J Psychopharmacol 25: 121-130.
14. Crippa JA, Loureiro SR, Baptista CA, Osório F (2007). Are there differences between early- and late-onset social anxiety disorder? Rev Bras Psiquiatr 29: 195-196. (Pubitemid 47075875)
15. Crippa JA, Zuardi AW, Busatto GF, Santos-Filho A, Graeff FG, Borduqui T et al (2008b). Grey matter correlates of cognitive measures of the simulated public speaking test in social anxiety spectrum: a voxel-based study. Eur Psychiatry 23(Suppl 2): 212.
16. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L et al (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417-426. (Pubitemid 38175159)
17. Crippa JA, Zuardi AW, Hallak JE (2010). Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 32(Suppl 1): S56-S66.
18. Crippa JA, Zuardi AW, Mart́n-Santos R, Bhattacharyya S, Atakan Z, McGuire P (2009). Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24: 515-523.
19. De Lima Osório F, Crippa JA, Loureiro SR (2007). A study of the discriminative validity of a screening tool (MINI-SPIN) for social anxiety disorder applied to Brazilian university students. Eur Psychiatry 22: 239-243. (Pubitemid 46729749)
20. De Lima Osório F, Crippa JA, Loureiro SR (2008). Self statements during public speaking scale (SSPS): cross-cultural adaptation for Brazilian Portuguese and internal consistency. Rev Psiq Cĺn 35: 207-211.
21. Del-Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM, Zuardi AW (2001). Confiabilidade teste-reteste da Entrevista Cĺnica Estruturada para o DSM-IVFVersão Cĺnica (SCID-CV) traduzida para o português. Rev Bras Psiquiatr 23: 156-159.
22. Filho AS, Hetem LA, Ferrari MC, Trzesniak C, Mart́n-Santos R, Borduqui T et al (2010). Social anxiety disorder: what are we losing with the current diagnostic criteria? Acta Psychiatr Scand 121: 216-226.
23. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I DisordersFClinican Version (SCID-CV). American Psychiatric Press: Washington, DC, USA.
24. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S et al (2009a). Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13: 421-432.
25. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al (2009b). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95-105.
26. Graeff FG, Parente A, Del-Ben CM, Guimarães FS (2003). Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421-432. (Pubitemid 36592145)
27. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX et al (2007). Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52: 1079-1087.
28. Hallak JE, Crippa JA, Quevedo J, Roesler R, Schröder N, Nardi AE et al (2010). National science and technology institute for translational medicine (INCT-TM): advancing the field of translational medicine and mental health. Rev Bras Psiquiatr 32: 83-90.
29. Hoffmann SG, Di Bartolo PM (2000). An instrument to assess self-statements during public speaking: scale development and preliminary psychometric properties. Behav Ther 31: 499-515. (Pubitemid 32116404)
30. Kessler RC (2007). The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry 68(Suppl 2): 10-19. (Pubitemid 46333561)
31. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S, Fisher S (1982). Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl) 77: 7-10. (Pubitemid 12091348)
32. Montgomery SA, Lecrubier Y, Baldwin DS, Kasper S, Lader M, Nil R et al (2004). European college of neuropsychopharmacology. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Eur Neuropsychopharmacol 14: 425-433. (Pubitemid 39141686)
33. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010). Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen canna-bis. Neuropsychopharmacology 35: 1879-1885.
34. Norris H (1971). The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
35. Osório Fde L, Crippa JA, Loureiro SR (2010). Further study of the psychometric qualities of a brief screening tool for social phobia (MINI-SPIN) applied to clinical and nonclinical samples. Perspect Psychiatr Care 46: 266-278.
36. Parente ACBV, Garcia-Leal C, Del-Ben C, Guimarães FS, Graeff FG (2005). Subjective and neurovegetative changes in health volunteers and panic patients performing simulated public speaking. Eur Neuropsychopharmacol 15: 663-671. (Pubitemid 41587418)
37. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004). Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175: 360-366. (Pubitemid 39361924)
38. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL (2009). Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 29: 14764-14769.
39. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
40. Schneier FR (2001). Treatment of social phobia with antidepres-sants. J Clin Psychiatry 62(Suppl 1): 43-48.
41. Soares VDEP, Campos AC, Bortoli VC, Zangrossi Jr H, Guimarães FS, Zuardi AW (2010). Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213: 225-229.
42. Zuardi AW (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.
43. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88. (Pubitemid 23099702)
44. Zuardi AW, Karniol IG (1981). Transcultural evaluation of a self-evaluation scale of subjective states. J Brasileiro Psiquiatr 131: 403-406.
45. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76: 245-250. (Pubitemid 12129400)